Ms Maryrose Delgallego Chuidian, DO | |
18th Medical Group, Unit 5142, Apo, AP 96368 | |
(315) 630-4780 | |
Not Available |
Full Name | Ms Maryrose Delgallego Chuidian |
---|---|
Gender | Female |
Speciality | General Practice |
Location | 18th Medical Group, Apo, Armed Forces Pacific |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1144539024 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 02003738A (Indiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ms Maryrose Delgallego Chuidian, DO 501 Jane Ln, Oakley, CA 94561-3998 Ph: (925) 207-3789 | Ms Maryrose Delgallego Chuidian, DO 18th Medical Group, Unit 5142, Apo, AP 96368 Ph: (315) 630-4780 |
News Archive
In 2011, the National Institute of Neurological Disorders and Stroke (NINDS) convened the Stroke Progress Review Group (SPRG) to conduct a final 10-year review of the state of stroke research.
A small minority of Americans surveyed consider the religious affiliation of the hospitals that treat them, but a majority said they didn't want religious doctrine dictating their healthcare choices, according to a study by researchers at the University of Colorado Anschutz Medical Campus.
BD (Becton, Dickinson and Company), a leading global medical technology company, along with Check-Points Health B.V., announced today that FDA 510(k) clearance was obtained for a molecular screening test for antibiotic-resistant carbapenemase-producing organisms on the fully-automated BD MAX System.
Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.
› Verified 9 days ago
Sarah Mcdonald, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 18th Medical Group, Unit 5142, Apo, AP 96368 Phone: 445-630-4089 | |
Jonathan Hajduk, DO General Practice Medicare: Medicare Enrolled Practice Location: Psc 2, Apo, AP 96264 Phone: 315-782-8035 | |
Francesann Hill, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 3214 East Santiago Avenue, Apo, AP 99703 Phone: 907-353-2497 | |
Justin Elan Palm, DO General Practice Medicare: Not Enrolled in Medicare Practice Location: Misawa Air Base 35th Mdg Flight, Building 99, Unit 5024, Apo, AP 96319 Phone: 017-677-6133 | |
Dr. Adriana Zamora, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: Building 99 Unit 5024, Misawa Ab, Japan, Apo, AP 96319 Phone: 315-226-6133 | |
Dr. Timothy A Gocke, D.O. General Practice Medicare: Medicare Enrolled Practice Location: 549th Hospital Center, Apo, AP 96271 Phone: 315-737-1131 |